DHRS12 inhibits the proliferation and metastasis of osteosarcoma via Wnt3a/β-catenin pathway

Reference

• 1. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 115(7), 1531–1543 (2010).
  Google Scholar
• 2. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat.Res. 152, 3–13 (2009).
  MedlineGoogle Scholar
• 3. Lewis IJ, Nooij MA, Whelan J et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized Phase III trial of the European osteosarcoma intergroup. J. Natl Cancer Inst. 99(2), 112–128 (2007).
  Medline CASGoogle Scholar
• 4. Faisham WI, Mat Saad AZ, Alsaigh LN et al. Prognostic factors and survival rate of osteosarcoma: a single-institution study. Asia Pac. J. Clin. Oncol. 13(2), e104–e110 (2017).
  MedlineGoogle Scholar
• 5. Min SK, Lee S-Y, Cho WH et al. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Ann. Surg. Oncol. 15(3), 906–914 (2008).
  MedlineGoogle Scholar
• 6. Bielack SS, Wulff B, Delling G et al. Osteosarcoma of the trunk treated by multimodal therapy: experience of the cooperative osteosarcoma study group (COSS). Pediatric Blood Cancer 24(1), 6–12 (2010).
  Google Scholar
• 7. Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr. Drugs 10(5), 315–327 (2008).
  MedlineGoogle Scholar
• 8. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol. 26(1), 1–18 (2007).
  Medline CASGoogle Scholar
• 9. Chandar N, Billig B, McMaster J, Novak J. Inactivation of p53 gene in human and murine osteosarcoma cells. Br. J. Cancer 65(2), 208–214 (1992).
  Medline CASGoogle Scholar
• 10. Aguilar S, Nye E, Chan J et al. Murine but not human mesenchymal stem cells generate osteosarcoma-like lesions in the lung. Stem Cells 25(6), 1586–1594 (2010).
  Google Scholar
• 11. Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy. Curr. Opin. Oncol. 25(4), 398–406 (2013).
  Medline CASGoogle Scholar
• 12. Zhou W, Hao M, Du X, Chen K, Wang G, Yang J. Advances in targeted therapy for osteosarcoma. Discov. Med. 17(96), 301–307 (2014).
  MedlineGoogle Scholar
• 13. Geller DS, Morris J, Revskaya E et al. Targeted therapy of osteosarcoma with radiolabeled monoclonal antibody to an insulin-like growth factor-2 receptor (IGF2R). Nucl. Med. Biol. 43(12), 812–817 (2016).
  Medline CASGoogle Scholar
• 14. Ballatori SE, Hinds PW. Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy. Signal Transduct. Target. Ther. 1, 16001 (2016).
  MedlineGoogle Scholar
• 15. Bartuma H, Nord KH, Macchia G et al. Gene expression and single nucleotide polymorphism array analyses of spindle cell lipomas and conventional lipomas with 13q14 deletion. Genes Chromosomes & Cancer 50(8), 619–632 (2011).
  Medline CASGoogle Scholar
• 16. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell 149(6), 1192–1205 (2012).
  Medline CASGoogle Scholar
• 17. Revill K, Wang T, Lachenmayer A et al. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology 145(6), 1424–1435.e1–25 (2013).
  Medline CASGoogle Scholar
• 18. Marina N. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9(4), 422441 (2004).
  Google Scholar
• 19. Qi XT, Li YL, Zhang YQ et al. KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells. Acta Pharmacol. Sin. 40(4), 546–555 (2018).
  MedlineGoogle Scholar
• 20. Yang Y, Han L, He Z et al. Advances in limb salvage treatment of osteosarcoma. J. Bone Oncol. 10, 36–40 (2018).
  MedlineGoogle Scholar
• 21. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev. Anticancer Ther. 6(7), 1075–1085 (2006).
  Medline CASGoogle Scholar
• 22. Bacci G, Picci P, Ferrari S et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 72(11), 3227–3238 (2015).
  Google Scholar
• 23. Saumet L, Deschamps F, Marec-Berard P et al. Radiofrequency ablation of metastases from osteosarcoma in patients under 25 years: the SCFE experience. Pediatr. Hematol. Oncol. 32(1), 41–49 (2015).
  Medline CASGoogle Scholar
• 24. Zhang HJ, Yang JJ, Lu JP et al. Use of intra-arterial chemotherapy and embolization before limb salvage surgery for osteosarcoma of the lower extremity. Cardiovasc. Intervent. Radiol. 32(4), 672–678 (2009).
  MedlineGoogle Scholar
• 25. Zhang P, Yang Y, Zweidler-McKay P, Hughes DP. Retraction: critical role of notch signaling in osteosarcoma invasion and metastasis. Clin. Cancer Res. 19(18), 5256–5257 (2013).
  Google Scholar
• 26. Wang S, Zhang D, Han S et al. Fibulin-3 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition and activating the Wnt/β-catenin signaling pathway. Sci. Rep. 7(1), 6215 (2017).
  MedlineGoogle Scholar
• 27. Huang Q, Gumireddy K, Schrier M et al. The microRNAs miR-373 and miR-520c promote tumor invasion and metastasis. Nat. Cell Biol. 10(2), 202–210 (2008).
  Medline CASGoogle Scholar
• 28. Song B, Wang Y, Xi Y et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 28(46), 4065–4074 (2009).
  Medline CASGoogle Scholar
• 29. Li W, Xie P, Ruan WH. Overexpression of lncRNA UCA1 promotes osteosarcoma progression and correlates with poor prognosis. J. Bone Oncol. 5(2), 80–85 (2016).
  MedlineGoogle Scholar
• 30. Song MA, Brasky TM, Weng DY, McElroy JP, Shields PG. Landscape of genome-wide age-related DNA methylation in breast tissue. Oncotarget 8(70), 114648–114662 (2017).
  MedlineGoogle Scholar
• 31. Jecmenica R, Grgic D, Matijevic M, Petrovic B. Nuclear and thermal hydraulic calculation of a representative I2S-LWR first core. Presented at: International Conference of the Croatian Nuclear Society. Zagreb: Croatian Nuclear Society, str. 072-1 (2016).
  Google Scholar
• 32. Rhim AD, Mirek ET, Aiello NM et al. EMT and dissemination precede pancreatic tumor formation. Cell 148(1–2), 349–361 (2012).
  Medline CASGoogle Scholar
• 33. Sánchez-Tilló E, Lázaro A, Torrent R et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 29(24), 3490–3500 (2010).
  Medline CASGoogle Scholar
• 34. Arenas MI, Romo E, Royuela M, Fraile B, Paniagua R. E-, N- and P-cadherin, and α-, β- and γ-catenin protein expression in normal, hyperplastic and carcinomatous human prostate. Histochem. J. 32(11), 659–667 (2000).
  Medline CASGoogle Scholar
• 35. Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a tumor-suppressor gene. Trends Biochem. Sci. 24(2), 73–76 (1999).
  Medline CASGoogle Scholar
• 36. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 68(10), 3645–3654 (2008).
  Medline CASGoogle Scholar
• 37. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J. Cell Biol. 147(3), 631–644 (1999).
  Medline CASGoogle Scholar
• 38. Katoh. Transcriptional mechanisms of WNT5A based on NF-κB, hedgehog, TGFβ, and notch signaling cascades. Int. J. Mol. Med. 23(6), 763–769 (2009).
  Medline CASGoogle Scholar
• 39. Zha L, Zhang J, Tang W et al. HMGA2 elicits EMT by activating the Wnt/β-catenin pathway in gastric cancer. Dig. Dis. Sci. 58(3), 724–733 (2013).
  Medline CASGoogle Scholar
• 40. Guo YH, Wang LQ, Li B et al. Wnt/β-catenin pathway transactivates microRNA-150 that promotes EMT of colorectal cancer cells by suppressing CREB signaling. Oncotarget 7(27), 42513–42526 (2016).
  MedlineGoogle Scholar